ADHD

The company presented data demonstrating that ADHD patients with mutations in nine genes had a clinically meaningful and statistically significant response to AEVI-001.


The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.

The international team of researchers also examined the genetic ties between personality traits and psychiatric disorders.

The Geisinger Health System team found 241 genes, including 17 new ones, which could be related to autism, schizophrenia, and other disorders.

NEW YORK (GenomeWeb) – Neuropsychiatric molecular diagnostics firm Assurex today said that it has secured a $25 million credit facility and $7 million in investments.
The funds will be used to increase clinical adoption of the Mason, Ohio-based firm's GeneSight products.

NEW YORK (GenomeWeb News) – The European Union has approved a project aimed at determining the causes of extreme aggressive behavior and is providing €6 million ($8 million) to the effort.

AssureRx Launches GeneSightRx ADHD
AssureRx Health this week launched a pharmacogenetic test, called GeneSightRx ADHD, for characterizing patients' response to a variety of attention deficit hyperactivity disorder drugs.

Researchers using exome sequencing to study ADHD found rare mutations they think may be causing a patient's anemia, raising the question of how to handle unrelated findings in sequencing studies.

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.